Drug intelligence / Profile preview

213Bi-matuzumab

Development stage: Unknown
Lead developer: Technical University of Munich
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravesical

Overview

213Bi-matuzumab is an experimental radiopharmaceutical and antibody-drug conjugate (ADC) consisting of the humanized monoclonal antibody matuzumab conjugated to the alpha-emitting radionuclide Bismuth-213 (^213Bi). Developed through a collaboration between the Technical University of Munich and the European Commission's Joint Research Centre, it specifically targets the epidermal growth factor receptor (EGFR), which is frequently overexpressed in various malignancies. Upon binding to EGFR on tumor cells, the conjugate delivers high-energy, short-range alpha radiation that induces lethal DNA double-strand breaks. This mechanism is particularly effective in treating hypoxic tumor cells and minimizing damage to surrounding healthy tissue. It has been primarily investigated for the intravesical treatment of BCG-refractory carcinoma in situ of the bladder, as well as for glioblastoma and squamous cell carcinoma.

Other names: 213Bi-anti-EGFR-mAb213Bi-DOTA-matuzumab

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)DNA

Beyond the preview

Go deeper on 213Bi-matuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 213Bi-matuzumab.

Explore the full profile